TY - JOUR
T1 - Rates and predictors of futile recanalization in patients undergoing endovascular treatment in a multicenter clinical trial
AU - Hussein, Haitham M.
AU - Saleem, Muhammad A.
AU - Qureshi, Adnan I
N1 - Publisher Copyright:
© 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Purpose: The phenomenon of futile recanalization, defined as lack of clinical benefit despite angiographic recanalization, is an important limitation of endovascular treatment for acute ischemic stroke. We aim to characterize the occurrence and predictors of futile recanalization in the endovascular arm of the Interventional Management of Stroke (IMS) III trial. Methods: Patients with near complete or complete recanalization (TICI grades 2b and 3) were divided according to functional outcome at 3 months into “meaningful recanalization,” defined as mRS score 0–2, and “futile recanalization,” mRS score 3–6. Multivariate analysis was performed to identify predictors of futile recanalization. Results: Futile recanalization was observed in 61 (47%) of 130. Compared to meaningful recanalization group, the futile recanalization group had higher proportion of women (62.3 vs. 43.5%; p = 0.032), higher incidence of diabetes mellitus (29.5 vs. 8.7%; p = 0.004) and coronary artery disease (27.9 vs. 13%; p = 0.05), higher baseline National Institutes of Health Stroke Scale (NIHSS) scores (median [range] 19 [11–31] vs. 15 [8–26], p < 0.001), higher baseline serum glucose (7.6 ± 2.6 vs. 6.7 ± 1.7 mmol/L; p = 0.039), and longer onset-to-start of endovascular treatment time (265.8 ± 48.3 vs. 239.2 ± 47.7 min; p = 0.007). In multivariate analysis, NIHSS (OR 1.3; 95% CI 1.1–1.4), female gender (OR 3.0; 95% CI 1.1–8.2), and onset-to-start of endovascular treatment time (OR 1.2; 95% CI 1.1–1.3) were independent predictors of futile recanalization. Conclusion: In IMS III, futile recanalization was common. Delay in endovascular treatment is the only modifiable risk factor. Additional strategies for non-modifiable risk factors—female gender and high NIHSS—need to be identified.
AB - Purpose: The phenomenon of futile recanalization, defined as lack of clinical benefit despite angiographic recanalization, is an important limitation of endovascular treatment for acute ischemic stroke. We aim to characterize the occurrence and predictors of futile recanalization in the endovascular arm of the Interventional Management of Stroke (IMS) III trial. Methods: Patients with near complete or complete recanalization (TICI grades 2b and 3) were divided according to functional outcome at 3 months into “meaningful recanalization,” defined as mRS score 0–2, and “futile recanalization,” mRS score 3–6. Multivariate analysis was performed to identify predictors of futile recanalization. Results: Futile recanalization was observed in 61 (47%) of 130. Compared to meaningful recanalization group, the futile recanalization group had higher proportion of women (62.3 vs. 43.5%; p = 0.032), higher incidence of diabetes mellitus (29.5 vs. 8.7%; p = 0.004) and coronary artery disease (27.9 vs. 13%; p = 0.05), higher baseline National Institutes of Health Stroke Scale (NIHSS) scores (median [range] 19 [11–31] vs. 15 [8–26], p < 0.001), higher baseline serum glucose (7.6 ± 2.6 vs. 6.7 ± 1.7 mmol/L; p = 0.039), and longer onset-to-start of endovascular treatment time (265.8 ± 48.3 vs. 239.2 ± 47.7 min; p = 0.007). In multivariate analysis, NIHSS (OR 1.3; 95% CI 1.1–1.4), female gender (OR 3.0; 95% CI 1.1–8.2), and onset-to-start of endovascular treatment time (OR 1.2; 95% CI 1.1–1.3) were independent predictors of futile recanalization. Conclusion: In IMS III, futile recanalization was common. Delay in endovascular treatment is the only modifiable risk factor. Additional strategies for non-modifiable risk factors—female gender and high NIHSS—need to be identified.
KW - Acute ischemic stroke
KW - Endovascular treatment
KW - Futile recanalization
KW - Mechanical thrombectomy
UR - http://www.scopus.com/inward/record.url?scp=85044374993&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044374993&partnerID=8YFLogxK
U2 - 10.1007/s00234-018-2016-2
DO - 10.1007/s00234-018-2016-2
M3 - Article
C2 - 29574600
AN - SCOPUS:85044374993
SN - 0028-3940
VL - 60
SP - 557
EP - 563
JO - Neuroradiology
JF - Neuroradiology
IS - 5
ER -